

REGENERON PHARMACEUTICALS INC  
Form 8-K  
March 05, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 4, 2014 (March 4, 2014)**

**REGENERON PHARMACEUTICALS, INC.**  
**(Exact name of registrant as specified in its charter)**

**New York**  
**(State or other jurisdiction**  
**of incorporation)**

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

**000-19034**  
**(Commission**

**13-3444607**  
**(I.R.S. Employer**

**File Number)**

**Identification No.)**

**777 Old Saw Mill River Road, Tarrytown, New York**  
**(Address of principal executive offices)**

**10591-6707**  
**(Zip Code)**

**Registrant's telephone number, including area code: (914) 847-7000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On March 4, 2014, at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) held in San Diego, California, data from a Phase 2a trial evaluating dupilumab, a human monoclonal antibody, in patients with atopic dermatitis were presented at an oral session by Prof. Diamant Thaçi, University of Lübeck, Germany. A copy of the slides is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Presentation entitled Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**REGENERON PHARMACEUTICALS,  
INC.**

/s/ Joseph J. LaRosa  
Joseph J. LaRosa  
Senior Vice President, General Counsel and  
Secretary

Date: March 4, 2014

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Presentation entitled Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study.